...commercialization. The company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC...
...the pivotal Phase II STARTRK-2 basket trial to treat several types of fusion-positive solid tumors. Milciclib...
...of the compound in combination with Nexavar sorafenib from Bayer AG (XETRA:BAYN) to treat HCC. Milciclib...

...commercialization. The company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC...
...trial to treat several types of fusion-positive solid tumors (see BioCentury Extra, Dec. 22) . Milciclib...
...of the compound in combination with Nexavar sorafenib from Bayer AG (XETRA:BAYN) to treat HCC. Milciclib...

...14 evaluable patients with refractory solid tumors in a Phase I trial showed that oral milciclib...
...cell lung cancer (NSCLC) and 4 cases of stable disease for up to 14 months. Milciclib...
...Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc (LSE:TILS), London, U.K. Product: Milciclib maleate ( PHA-848125AC...

...will begin in May an open-label, international Phase IIa trial to evaluate 100 mg oral milciclib...
...to respond to or are intolerant of standard of care (SOC). Patients will receive once-daily milciclib...
...Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc (LSE:TILS), London, U.K. Product: Milciclib maleate ( PHA-848125AC...

...trial of milciclib maleate ( PHA-848125AC ) to treat refractory solid tumors. In 14 evaluable patients, milciclib...
...month of milciclib to treat refractory hepatocellular carcinoma (HCC). The company has exclusive rights to milciclib...
...Lieu milciclib maleate Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin dependent kinase (CDK) Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1) PHA-848125AC...

...TRKA inhibitor, in Phase II testing for dermatitis and psoriasis. Nerviano Medical Sciences s.r.l. has milciclib maleate...